ForteBio Launches Dip and Read Anti-Human Fab-CH1 Biosensor to Accelerate Human Biotherapeutic Drug Development

Wed Jan 9, 2013 5:00pm EST

* Reuters is not responsible for the content in this press release.

http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130109:nBw096480a

PORT WASHINGTON, N.Y.--(Business Wire)--
ForteBio, a division of Pall Life Sciences and a leading supplier of label-free
technology that accelerates the development of biotherapeutic and pharmaceutical
products, today announced the launch of its Dip and Read Anti-Human Fab-CH1
biosensor. The new biosensor enables an easy and rapid method for quantitation
and kinetic characterization of human Fab, F(ab`)2 and IgG - critical processes
in drug discovery. Dip and Read biosensors are designed for use on ForteBio`s
Octet and BLItz instrumentation systems. 

"The detection and characterization of human IgG is of paramount importance to
research scientists," said Christopher Silva, the ForteBio division`s vice
president of marketing. "However, traditional approaches to quantitation and
kinetic characterization have been cumbersome, slow and expensive. Our new
Anti-Human Fab-CH1 biosensor carries the popular CaptureSelect IgG-CH1 ligand
from BAC BV, a company that provides affinity tools widely used in purification
of antibodies and antibody fragments. The new biosensor offers researchers
unparalleled ease of use and time-to-result in a wide range of laboratory
applications, enabling improved laboratory workflow and cost-efficiency." 

The Anti-Human Fab-CH1 biosensor consists of a pre-immobilized high-affinity,
anti-human CH1 affinity ligand that binds specifically to the CH1 domain of all
four human IgG subclasses independent of the type of light chain. Its unique
selectivity provides solid coverage of any human IgG derived Fab fragment
without interference of notorious product-related contaminants like
over-expressed free light chains. The high specificity of the biosensor enables
direct analysis of human Fab/F(ab`)2/IgG in crude lysates, column eluants, cell
lysates and cell culture supernatants, providing a time-saving alternative to
traditional analytical methods. 

The Octet family of products is based on ForteBio`s proprietary Bio-Layer
Interferometry (BLI) technology. It incorporates disposable optical Dip and Read
biosensors that measure multiple interactions in parallel, without the use of
detection agents. For single-sample analysis, ForteBio recently launched its
BLItz platform. The new platform revolutionizes the use of label-free protein
analysis by making it more accessible and cost-effective for individual bench
scientists in biotherapeutic discovery, process development and academic
research. 

About ForteBio

ForteBio is a division of Pall Life Sciences. ForteBio provides analytical
systems to accelerate biotherapeutic drug discovery and development. These
systems enable real-time, label-free analysis of biomolecular interactions,
providing information on affinity, kinetics and concentration. ForteBio`s
analytical capabilities enable significantly easier, faster and better
characterization of drug candidates, thus providing greater value in drug
development applications where existing methods have limitations in throughput,
performance and cost. For more information, visit www.fortebio.com. 

About Pall Life Sciences

Pall Life Sciences, a division of Pall Corporation (NYSE:PLL), provides
cutting-edge products and services to meet the demanding needs of customers
discovering, developing and producing biotech drugs, vaccines and classic
pharmaceuticals. Its membranes and membrane devices optimize detection and
sample preparation in the drug research, clinical diagnostics, genomics, and
proteomics markets. Pall Life Sciences is a leading provider of separation
systems and single-use filtration and purification technologies to
pharmaceutical and biotechnology companies to support faster development of new
drugs and vaccines that are safer and require less energy and water to produce.
Pall Life Sciences` technologies are also used in clinical institutions and the
food and beverage industries. 

About Pall Corporation

Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader
providing solutions to meet the critical fluid management needs of customers
across the broad spectrum of life sciences and industry. Pall works with
customers to advance health, safety and environmentally responsible
technologies. The company`s engineered products enable process and product
innovation and minimize emissions and waste. Pall Corporation is an S&P 500
company serving customers worldwide. Pall has been named a "top green company"
by Newsweek magazine. To see how Pall is helping enable a greener, safer, more
sustainable future, follow us on Twitter @PallCorporation or visit
www.pall.com/green.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130109006480/en/

Doug Novarro
Pall Corporation
Corporate Public Relations
516-801-9944
Doug_novarro@pall.com
Follow us on Twitter @pallcorporation
or
Gemma Milan
ForteBio
650-289-6800
Gemma_milan@pall.com

Copyright Business Wire 2013